Powered by
-ACETO Subsidiary, Rising Pharmaceuticals, Launches Efavirenz Capsules, 50mg and 200mg

PORT WASHINGTON - ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Healthproducts, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched the first generic for Efavirenz Capsules, 50mg and 200mg, an FDA-approved generic version of the reference listed drug, Sustiva from Bristol Myers Squibb, which in combination with

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox